Study Identification

Helping to identify new study opportunities for clinical research sites

WCG PharmaSeek’s goal is to identify new study opportunities for your research site. Each year we secure over 550 new study opportunities in virtually all therapeutic areas for our Network. Our dedicated business development team is solely committed to growing your site’s pipeline. With no long-term contracts and no fees until you are actively enrolling patients on a trial, our interests are aligned with you – the site. Unlike a broker that charges fees before the site is selected for the trial or enrolling any patients, WCG PharmaSeek only receives compensation if the investigative research site successfully enrolls subjects into the study. Our intent is to allow our sites to focus on patient care and enrollment while we search for new research opportunities.

Ready to get started?

Sites are approved for the network after passing a six-step selection process. After the site signs a CDA and a network agreement, WCG PharmaSeek begins by sending study opportunities we have identified from sponsors and CROs to determine site interest. Once a match is made, WCG PharmaSeek expedites study start-up timelines and manages the ongoing process of budgeting, contracting and regulatory submissions. After a site is initiated on a clinical trial, WCG PharmaSeek assists with patient recruitment and acquires payments on behalf of the site.

Benefits of working with WCG PharmaSeek:

  • Access to hundreds of new clinical trials each year
  • Proven streamlined and accelerated study start-up process
  • Individually assigned accounting manager to handle all site payments
  • Access to new sponsors/CROs through established relationships
  • No long-term or exclusive agreements
  • Assistance with sponsor/CRO communication and study updates

Secure more study opportunities for your research site

Want to learn more? Fill out this form for a quick consultation with our site development manager to learn how we can help grow your study pipeline.